ABBV vs BIIB
AbbVie (ABBV) and Biogen (BIIB) compared side by side. AbbVie (ABBV) is larger, with a market cap of $504.8B versus $37.0B for Biogen, about 13.6 times the size. On trailing earnings, BIIB is cheaper at 44.5x versus 80.7x for ABBV.
Head to head
| Metric | ABBV | BIIB |
|---|---|---|
| Market cap | $504.8B | $37.0B |
| P/E (TTM) | 80.7x | 44.5x |
| Forward P/E | 17.6x | 15.2x |
| Revenue (TTM) | $64.4B | $10.0B |
| Revenue growth | 10.2% | 3.4% |
| Gross margin | 72.8% | 78.3% |
| Operating margin | 40.0% | 25.1% |
| Free cash flow | $18.2B | $2.5B |
| Dividend yield | 2.42% | None |
| 1-year return | +28.9% | +67.0% |
| 5-year return (annual) | +25.6% | -1.1% |
| Max drawdown | -45% | -90% |
| FI Handbook grade | B | C |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
$10.0K
$20.0K
20222023202420252026
ABBV vs BIIB FAQ
Which is bigger, ABBV or BIIB?
AbbVie (ABBV) is larger, with a market cap of $504.8B versus $37.0B for Biogen, about 13.6 times the size.
Is ABBV or BIIB cheaper?
On trailing earnings, BIIB is cheaper at 44.5x versus 80.7x for ABBV. A lower P/E can reflect slower expected growth, so compare growth and margins too.
Which stock performed better over the past year, ABBV or BIIB?
BIIB returned +67.0% over the past year including dividends, versus +28.9% for ABBV, through October 23, 2026.
Which pays a higher dividend, ABBV or BIIB?
ABBV yields 2.42%; BIIB does not pay a dividend.